Contributed Abstracts
Hall 1 (Salt Palace Convention Center)
Long-Term Remission After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Active Disease
Renate Arnold, MD, Charite University Medicine Berlin;
Philipp Hemmati, MD, Charité - Universitaetsmedizin Berlin;
Philipp le Coutre, Charité University Medicine Berlin;
Lam Vuong, Charité University Medicine Berlin;
Christian Jehn, Charitè University Medicine Berlin;
Benjamin Ostendorf, Charitè Universitiy Medicine Berlin;
Il-Kang Na, Charité University Medicine Berlin;
Olaf Penack, Charitè University Medicine Berlin;
Bernd Dörken, Charité University Medicine Berlin;
Theis Terwey, MD, Charité Universitätsmedizin Berlin;
Gero Massenkeil, Klinikum Gütersloh
Allogeneic Transplantation for Ph+ Acute Lymphoblastic Leukemia (ALL): Impact of Conditioning Intensity, Tyrosine Kinase Inhibitors (TKI) and Minimal Residual Disease (MRD)
Veronika Bachanova, MD, University of Minnesota Medical Center, Fairview;
David Marks, MD PhD, University Hospitals Bristol NHS Trust;
Mei-Jie Zhang, PhD, Medical College of Wisconsin;
Hailin Wang, MPH, Center for International Blood and Marrow Transplant Research;
Daniel J. Weisdorf, MD, University of Minnesota
Aberrant Expression of Myeloid Antigens Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia Patients with Short Survival
Bakul I Dalal, MD FRCPC, Vancouver General Hospital;
Areej Al Mugairi, MD FRCPC, Vancouver General Hospital;
Adam Bryant, MBBS, University of British Columbia;
Sally Lau, University of British Columbia;
Steven Pi, Vancouver General Hospital;
Nikisha S Khare, Vancouver General Hospital;
Jason Pal, Vancouver General Hospital;
Yasser Abou Mourad, MD, FRCPC, University of British Columbia
Early Versus Late Allogeneic Hematopoietic Cell Transplantation in Patients with AML - Results From the Randomized AML 2003 Trial
Gerhard Ehninger, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Martin Bornhäuser, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Markus Schaich, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Christoph Röllig, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Kerstin Schaefer-Eckart, Klinikum Nürnberg Nord;
Mathias Hänel, Klinikum Chemnitz gGmbH;
Hermann Einsele, University Hospital;
Norbert Schmitz, ASKLEPIOS Hospital St. Georg;
Wolf Rösler, Universitätsklinik Erlangen;
Jiri Mayer, Univ Hospital;
Anthony D. Ho, University of Heidelberg;
Walter E. Aulitzky, Robert-Bosch-Krankenhaus;
Michael Kramer, Universitätsklinikum Carl Gustav Carus;
Uwe Platzbecker, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Hubert Serve, Goethe-University Frankfurt;
Matthias Stelljes, University of Münster;
Albrecht Reichle, University of Regensburg;
Claudia D Baldus, Charité Berlin;
Wolfgang E Berdel, University of Münster;
Christian Thiede, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Johannes Schetelig, Universitätsklinikum Carl Gustav Carus der TU Dresden
Mixed Phenotype Acute Leukemia: Patient Outcomes According to the WHO 2008 Classification
Amir Hamdi, MD, The University of Texas MD Anderson Cancer Center;
Chi Young Ok, MD, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center;
Sa A Wang, MD, The University of Texas MD Anderson Cancer Center;
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center;
L. Jeffrey Medeiros, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Jeffrey L Jorgensen, MD, The University of Texas MD Anderson Cancer Center;
Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center
Long-Term Outcomes of Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Leukemia Based On Conditioning Regimen without Total Body Irradiation
Amir Ali Hamidieh, M.D., Tehran University of Medical Sciences;
Maryam Behfar, M.D., Tehran University of Medical Sciences;
Kamran Alimoghaddam, M.D., Tehran University of Medical Sciences;
Sirous Tayebi, Tehran University of Medical Sciences;
Simindokht Basirpanah, Tehran University of Medical Sciences;
Ashraf sadat Hosseini, Tehran University of Medical Sciences;
Arash Jalali, Tehran University of Medical Sciences;
Ardeshir Ghavamzadeh, M.D., Tehran University of Medical Sciences
Usefulness of 3 Monthly Marrow Evaluations in Predicting Relapse of Myeloid Malignancies After HCT
Katalin Kelemen, MD, PhD, Mayo Clinic;
Veena Fauble, MD, Banner/MD Anderson Blood & Marrow Transplant Program;
Lisa Ostrosky Sproat, MD, MSW, Mayo Clinic Arizona;
Jose Leis, MD, PhD, Mayo Clinic Arizona;
Pierre Noel, MD, Mayo Clinic Arizona;
Jared Klein, MD, Loyola University Medical Center;
Raoul Tibes, MD, PhD, Mayo Clinic Arizona;
James Slack, MD, Mayo Clinic Arizona;
Roberta Adams, MD, Mayo Hospital;
Ruben A. Mesa, MD, FACP, Mayo Clinic Arizona;
Nandita Khera, MD, Mayo Clinic Arizona
Impact of Dose Intensification of FluBu2 to FluBu4 On Transplant Related Mortality, Relapse, and Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia in Remission
John Magenau, M.D., University of Michigan;
Attaphol Pawarode, M.D., University of Michigan;
Daniel R. Couriel, M.D., University of Michigan;
Gregory Yanik, M.D., University of Michigan;
Shin Mineishi, M.D., University of Alabama at Birmingham, Birmingham, AL;
Thomas Braun, Ph.D., Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI;
Pavan Reddy, M.D., University of Michigan;
James L.M. Ferrara, M.D., D.Sc., University of Michigan;
David Frame, PharmD, Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI;
Sung Won Choi, M.D., University of Michigan;
Andrew C. Harris, M.D., University of Michigan;
Carrie L. Kitko, M.D., University of Michigan;
James A Connelly, M.D., University of Michigan;
John Levine, MD, MS, Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI;
Steven C. Goldstein, M.D., University of Michigan
Association of Mannose Binding Lectin (MBL) Levels and Invasive Fungal Disease (IFD) in Hematologic Malignancy Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) or Receiving Chemotherapy
Mary Mansour Riwes, DO, University of Florida;
Helen Leather, BPharm, University of Florida;
Dan Neal, M.S., University of Florida;
Clayton Bennett, University of Florida;
Michele Sugrue, University of Florida;
Christina Cline, University of Florida;
Joe Stokes, University of Florida;
John Hiemenz, MD, University of Florida;
Jack Hsu, MD, University of Florida;
John R Wingard, MD, University of Florida
Clofarabine-Based Salvage Therapy and Conditioning Regimen in Patients with Relapsed or Refractory AML
Jan Moritz Middeke, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Stefani Parmentier, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Nael Alakel, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Markus Schaich, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Christian Thiede, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Uwe Platzbecker, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Christoph Röllig, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Mathias Hänel, Klinikum Chemnitz gGmbH;
Gernot Stuhler, Medizinische Klinik und Poliklinik II der Universität Würzburg;
Anke Morgner, Klinikum Chemnitz gGmbH;
Ute Eulenstein, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Gerhard Ehninger, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Martin Bornhäuser, Universitätsklinikum Carl Gustav Carus der TU Dresden;
Johannes Schetelig, Universitätsklinikum Carl Gustav Carus der TU Dresden
Autologous STEM CELL Transplant (ASCT) As an Effective POST-Remission Consolidation Strategy for Good Risk ACUTE Myeloid Leukemia (AML) Patients
Jan Cerny, MD, PhD, University of Massachusetts;
Muthalagu Ramanathan, MD, UMASS Memorial University Campus;
Andrew Evens, DO, Umass memorial medical Center;
William Walsh, MD, University of Massachusetts Memorial Medical Center;
Alan Rosmarin, UMas Memorial;
Rajneesh Nath, MD, UMass Memorial Medical Center
Anti-CD45 Pretargeted Radioimmunotherapy Prior to Bone Marrow Transplantation without Total Body Irradiation Facilitates Engraftment From Haploidentical Donors and Prolongs Survival in a Disseminated Murine Leukemia Model
Johnnie J. Orozco, MD, PhD, Fred Hutchinson Cancer Research Center;
Aimee Kenoyer, BS, Fred Hutchinson Cancer Research Center;
Ethan Balkin, PhD, University of Washington;
Donald K. Hamlin, BS, University of Washington;
Scott Wilbur, PhD, University of Washington;
Darrell R. Fisher, PhD, Pacific Northwest National Laboratory;
Raya Mawad, MD, Fred Hutchinson Cancer Research Center;
Shani L. Frayo, BS, Fred Hutchinson Cancer Research Center;
Mark D. Hylarides, PhD, Fred Hutchinson Cancer Research Center;
Damian J Green, MD, Fred Hutchinson Cancer Research Center;
Ajay K. Gopal, MD, Fred Hutchinson Cancer Research Center;
Paul V. O'Donnell, MD, PhD, FACP, Fred Hutchinson Cancer Research Center;
Brenda M. Sandmaier, MD, Fred Hutchinson Cancer Research Center;
Oliver W. Press, MD, PhD, Fred Hutchinson Cancer Research Center;
John M. Pagel, MD, PhD, Fred Hutchinson Cancer Research Center
Allogeneic HSCT From Unrelated and Sibling Donors Are Equal for Children with Acute Lymphoblastic Leukemia
Christina Peters, MD, PhD, St. Anna Children's Hospital;
Andre Schrauder, University Hospital Schleswig-Holstein;
Arend von Stackelberg, Charité;
Martin Schrappe, University Hospital Schleswig-Holstein;
Peter Bader, Klinik Fur Kinderheilkunde III;
Brigitte Strahm, University Hospital;
Wolfram Ebell, University Hospital Charite-Virchow;
Rupert Handgretinger, Children's University Hospital;
Karl-Walter Sykora, University Hospital;
Johanna Schrum, University Hospital UKE;
Bernhard Kremens, University Hospital;
Susanne Matthes-Leodolter, St. Anna Children's Hospital;
Karoline Ehlert, University Children´s Hospital;
Michael Albert, Dr. von Haunersches Kinderspital;
Roland Meisel, University Hospital;
Tayfun Guengoer, University Children's Hospital;
Klaus Daniel Stachel, Children`s Hospital, University of Erlangen;
Wolfgang Holter, St. Anna Children's Hospital;
Bernd Gruhn, University Hospital;
Ansgar Schulz, Universitatsklinikum Ulm Klinik fur Kinder;
Ulrike Poetschger, St. Anna Children's Cancer Research Institute;
Martin Zimmermann, Hannover Medical School;
Thomas E Klingebiel, Zentrum Fuer Kinder Und Jugendmedizin
Second Allogeneic Stem-Cell Transplantation (SCT) From a Different Donor for the Treatment of Relapsed AML and MDS After a Previous Allogeneic SCT
Avichai Shimoni, MD, Chaim Sheba Medical Center;
Noga Shem-Tov, MD, Chaim Sheba Medical Center;
Yulia Volchek, MD, Chaim Sheba Medical Center;
Ronit Yerushalmi, MD, Chaim Sheba Medical Center;
Arnon Nagler, MD, Chaim Sheba Medical Center
Clofarabine Salvage in Refractory Acute Myeloid Leukemia Before Allogeneic Stem Cell Tranplant
Lisa Ostrosky Sproat, MD, MSW, Mayo Clinic Arizona;
Jeff Betcher, BS Pharm, Mayo Clinic Arizona;
Rochelle Chiffelle, DNP, Mayo Clinic Arizona;
Susan Gerber, PA-C, Mayo Clinic Arizona;
Brooke Loewen, PA-C, Mayo Clinic Arizona;
Jane Olsen, NP, Mayo Clinic Arizona;
Jane Palmer, NP, Mayo Clinic Arizona;
Angela Toro, NP, Mayo Clinic Arizona;
Roberta Adams, MD, Mayo Clinic Arizona;
Veena Fauble, MD, Mayo Clinic Arizona;
Nandita Khera, MD, Mayo Clinic Arizona;
Jose Leis, MD, PhD, Mayo Clinic Arizona;
Pierre Noel, MD, Mayo Clinic Arizona;
Ruben A. Mesa, MD, FACP, Mayo Clinic Arizona;
Craig Reeder, MD, Mayo Clinic Arizona;
Raoul Tibes, MD, PhD, Mayo Clinic Arizona;
James Slack, MD, Mayo Clinic Arizona
The Histone Deacetylase Inhibitor SAHA Sensitizes AML Cells to a Combination of Nucleoside Analogs and the DNA-Alkylating Agent Busulfan
Guiyun Wang, PhD, U. T. M. D. Anderson Cancer Center;
Ben Valdez, PhD, UT MD Anderson Cancer Center;
Yang Li, MS, U. T. M. D. Anderson Cancer Center;
Jose R Dominguez, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, M. D. Anderson Cancer Center
Findings From BONE Marrow Biopsy Pathology Show Plasma CELL Disorders Have Smaller CORE Lengths; Mastocytosis, Myeloproliferative Disorder, and Chronic Lymphocytic Leukemia Have Higher Hemodilution Rates
Vance Ward, RN, BSN, Washington University Medical Center;
Barbara Press, RN, BSN, OCN, Washington University;
Jim Wischmeier, RN, BSN, OCN, washinton University;
Patty Cliver, RN, OCN, Washington University;
Kelly Garavaglia, RN, Washington University;
Cheryl Wilson, RN, BSN, OCN, Washington University;
Greg Voelkel, RN, BSN, Washington University;
Charles Eby, MD, Washington University
Pre-Transplant Consolidation Chemotherapy Does Not Improve Outcomes Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) for Acute Myeloid Leukemia (AML) in CR1
Erica Warlick, MD, University of Minnesota;
Kristjan Paulson, MD, FRCPC, University of Manitoba;
Ruta Brazauskas, PhD, Center for International Blood and Marrow Transplant Research;
Xiaobo Zhong, MS, Center for International Blood and Marrow Transplant Research;
Mary Eapen, MD, MS, Medical College of Wisconsin;
Daniel J. Weisdorf, MD, University of Minnesota;
Mark R Litzow, MD, Mayo Clinic
A Prospective Study of Allogeneic Transplant for Older Patients with Acute Myelogenous Leukemia (AML) Indicates That Unrelated Donor Transplants Are As Efficacious As Related Donor, with Favorable Outcomes for Intermediate Risk Disease
Gregory Yanik, M.D., University of Michigan;
John Magenau, M.D., University of Michigan;
Steven C. Goldstein, MD, University of Michigan;
Attaphol Pawarode, M.D., University of Michigan;
Moshe Talpaz, MD, University of Michigan Medical Center;
John Levine, MD, MS, University of Michigan Medical Center;
Sung Choi, M.D., University of Michigan Medical Center;
Carrie L. Kitko, M.D., University of Michigan;
Daniel R. Couriel, M.D., University of Michigan
![[Visit Client Website]](images/banner.gif)